 Scott Garverick Carton Service - Packaging Insights Vice President Sales Visit Website |
As the vice president of Sales for Carton Service-Packaging Insights, Scott Garverick is responsible not only for the sales leadership of CS-PI’s cartoning division, but he also spearheads marketing and strategic alliances for the company’s pharmaceutical packaging arm. Garverick initiated CS-PI’s foray and implementation of the company’s venture into pharmaceutical contract packaging 12 years ago. His role with CS-PI began 23 years ago in an apprenticeship program in which he worked and trained in each CS-PI department. After completing the program, Garverick’s first 10 years of tenure were dedicated to generating new business for CS-PI. Garverick was then made an officer of the company and has been vice president of sales since 1996. Carton Service-Packaging Insights, which will be announcing its new corporate name this year, delivers original, turnkey contract and compliance packaging solutions for mid-sized and virtual pharmaceutical and nutraceutical companies throughout North America. CS-PI offers customers access to two in-house Design Teams, providing creative structural design solutions and innovative graphic designs.
|
Patient Compliance Packaging Q&A
-
Asked July 13th, 2009
It is the ultimate responsibility of the NDA/ANDA holder as they own the product. The owner of the NDA/ANDA will decide which components and materials will be selected to package their product. To demonstrate equivalency of materials when a change is desired, stability testing will always be an acceptable method for demonstrating equivalency. However, this is not always cost or time effective when equivalency can be demonstrated through science. It is very advantageous for the drug manufacturer, contract packager, and material provider to leverage their resources to build the case for equivalency. In many cases, data such as the MVTR (moisture-vapor transmission rate) provided by the material provider may be used. At other times, the contract packager may provide additional data from engineering studies, such as placing “moisture dots” within the sealed primary package to confirm moisture protection. Data from these tests can be compared with the existing specification, allowing the contractor and customer to agree the two are equivalent prior to the customer filing with FDA via an annual report or another necessary filing.
